The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dietary links with symptoms in early-phase immune checkpoint combinations trials.
 
Goldy George
No Relationships to Disclose
 
Sarina Piha-Paul
Consulting or Advisory Role - CRC Oncology; Lilly
Research Funding - ABM (Inst); Alkermes (Inst); Aminex (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cancer Prevention Research Institute of Texas (CPRIT) (Inst); Chugai Pharma (Inst); Cullinan Oncology (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Epigenetix (Inst); Genmab (Inst); Gilead Sciences (Inst); Immunity Bio, Inc. (Inst); Immunomedics (Inst); Incyte (Inst); Innovent Biologics (Inst); Jazz Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Loxo (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); Nectin Therapeutics (Inst); NIH/NCI (Inst); NRG Oncology (Inst); Nurix (Inst); OncoNano Inc (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); ProfoundBio (Inst); Puma Biotechnology (Inst); Purinomia (Inst); Replimune (Inst); Roche/Blueprint (Inst); Seagen (Inst); Strand Therapeutics, Inc. (Inst); Tallac Therapeutics, Inc. (Inst); Toragen Therapeutics, Inc. (Inst); TransThera Biosciences (Inst); ViroMissile, Inc. (Inst); Xencor (Inst)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Ecaterina Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics; Fate Therapeutics; Mersana; PMV Pharma; Summit Therapeutics
Speakers' Bureau - PMV Pharma
Research Funding - A2A Pharmaceuticals (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Dragonfly Therapeutics (Inst); Fate Therapeutics (Inst); Genentech (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); Mersana (Inst); ModeX Therapeutics (Inst); Pfizer (Inst); PMV Pharma (Inst); Poseida (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Sotio (Inst); Triumvira Immunologics, Inc (Inst); Volastra Therapeutics (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Rain Oncology; Triumvira Immunologics, Inc
 
Apostolia Tsimberidou
Consulting or Advisory Role - Avstera; BioEclipse Therapeutics; BrYet; Macrogenics; Nex-I; Vincerx Pharma
Research Funding - Abbvie (Inst); Agenus (Inst); Anaveon (Inst); BrYet; IMMATICS (Inst); Macrogenics (Inst); Novocure (Inst); OBI Pharma (Inst); Orionis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Tachyon (Inst); Tempus (Inst); Tempus (Inst); Tvardi Therapeutics (Inst); Vividion Therapeutics (Inst)
 
Grace Appleton
No Relationships to Disclose
 
Timothy Yap
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Aeneid Therapeutics; Almac Group; Alterome Therapeutics; Amgen; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Atavistik; Athenahealth; Atrin Pharmaceuticals; Avenzo; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; Bicycle Therapeutics; BioCity Pharma; Bloom Burton; Blueprint Medicines; Bluestar Bio; Boxer; BridGene Biosciences; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research Horizons; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clasp; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; DAiNA; Dark Blue Therapeutics; Dawn Manco; Debiopharm Group; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Eikon; Ellipses Pharma; EMD Serono; Entos; F-Star; Flagship Pioneering; Forbion; FoRx Therapeutics; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Grey Wolf Therapeutics; Guardant Health; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Jazz Pharmaceuticals; Joint Scientific Committee for Phase I Trials in Hong Kong; Joint scientific Committee for Phase I Trials in Hong Kong; Kyn therapeutics; Kyowa Kirin International; Lumanity; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Plexium; Pliant; Prelude Therapeutics; ProLynx; Protai Bio; PSIM; Radiopharma Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; SERVIER; Stablix; Synnovation; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; techspert.io; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome; Trevarx Biomedical; Varian Medical Systems; Veeva; Versant Health; Vibliome Therapeutics; Vivace Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding - 858 Therapeutics (Inst); Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group (Inst); Aprea Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Boundless Bio; BridGene Bioscience (Inst); Circle Pharma (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); CPRIT; Cyteir (Inst); Department of Defense; EMD Serono (Inst); Exelixis; F-Star (Inst); Forbius (Inst); Genentech (Inst); Gilead Sciences; GlaxoSmithKline (Inst); Golfers Against Cancer; Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); NIH/NCI; Novartis (Inst); Pfizer (Inst); Pliant; Prelude Therapeutics; Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche; Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); SpringWorks Therapeutics (Inst); Synnovation; Tango Therapeutics; Tesaro (Inst); V Foundation; Vivace Therapeutics (Inst); Zenith Epigenetics (Inst); Zentalis
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; Guardant Health; Incyte; Jazz Pharmaceuticals; LegoChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; Protai; Ribometrix; Seagen; Tempus; Theratechnologies; Zentalis
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology
 
David Hong
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - crossbridge Bio; MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - 280 Bio; Acuta; Alphasights; Amgen; Bayer; Boxer Capital; Bristol Myers Squibb Company; Children's Oncology Group; COR2ed; Cowen Group In; Crossbridge Bio; EcoR1 Capital; Erasca, Inc; Gerson Lehrman Group; GroupH; Guidepoint Pharmacy; H.C. Wainwright & Co. (HCW Precision); Immunogenesis; Janssen; Kestrel Therapeutics; Medacorp; Medscape; Mirati Therapeutics; Orbi Capital; Pfizer; Pharma Intelligence; Revolution Medicines; Sanofi and Genzyme US Companies; T-Knife; Travistock Group; WebMD; WebMed; Yiling Pharmaceutical
Research Funding - 280 Bio; Abbvie (Inst); Adaptimmune; Adlai Nortye; Amgen (Inst); Astellas Medivation; AstraZeneca; Bayer (Inst); BeiGene; BeiGene (Inst); BioBridge (Inst); Biomea Fusion (Inst); Bristol Myers Squibb (Inst); Deciphera Pharmaceuticals Inc. (Inst); E.R. Squibb & Sons LLC (Inst); Endeavor BioMedicines; Erasca, Inc; Exelixis (Inst); Genentech; Genentech (Inst); Genezyme Corp (Sanofi) (Inst); Immunogenesis; Incyte (Inst); Janssen (Inst); Lilly; Merck Sharp & Dohme LLC (Inst); Mirati Therapeutics (Inst); National Cancer Institute; Navie Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Revolution Medicines; Roche; ST Cube; VM Pharma; Yiling Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; BeiGene (I); Mirati Therapeutics; Society for Immunotherapy of Cancer; Telperian